Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Harvard Business School
Medtronic
Mallinckrodt
Dow

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

See Plans and Pricing

« Back to Dashboard

AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Docket   Start Trial Date Filed 2014-06-02
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties ASTRAZENECA AB; MYLAN PHARMACEUTICALS INC.
Patents 6,395,767; 7,951,400; 8,628,799; RE44,186
Attorneys Charles E. Lipsey; Daniel M. Silver; David Ellis Moore; Douglas H. Carsten; Joshua Mack; Maximilienne Bishop; Michael P. Kelly; Richard L. Horwitz
Link to Docket External link to docket
Small Molecule Drugs cited in AstraZeneca AB v. Mylan Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-06-02 1 Method.” The RE’186 patent is a reissue of U.S. Patent No. 6,395,767 (“the ’767 patent”), which issued on…RE44,186 (“the RE’186 patent”) and U.S. Patent No. 7,951,400 (“the ’400 patent”). 3. …expiration of the RE’186 patent and U.S. Patent No. 8,628,799 (“the ’799 patent”). … This is an action for patent infringement arising under the patent laws of the United States, … PATENTS-IN-SUIT 13. On April 30, 2013, the U.S. Patent and Trademark Office External link to document
2014-09-23 21 than April 30, 2014. Date of Expiration of Patent: 7,951,400 (November 30, 2028); RE44,186 (July 31, 2023… Date of Expiration of Patent: 7,951,400 (November 30, 2028) … Amended Supplemental information for patent cases involving an Abbreviated New Drug Application… AMENDED SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG… 2 June 2014 1:14-cv-00696 830 Patent None District Court, D. Delaware External link to document
2014-11-05 26 2014, alleging patent infringement of U.S. Patent Nos. 7,951,400 ("the '400 Patent"), RE44,186…expiration of the '400 Patent, the '186 Patent, and the '799 Patent. (Id. iii! 1-3.) …RE44,186 ("the '186 Patent"), and 8,628,799 ("the '799 Patent"). (D.I. 1.) The … for a drug with patent protection triggered a statutory cause of action for patent holders. 8 Thus, … claimed in a patent or the use of which is claimed in a patent ... if the purpose External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Boehringer Ingelheim
Baxter
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.